Literature DB >> 12389012

Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. A review.

Bente Juel Riis1, Hans-Jørgen Lehmann, Claus Christiansen.   

Abstract

This article is focused on the use of norethisterone acetate as progestogen in hormone replacement therapy. Emphasis is made on the fact that the primary reason for adding a progestogen to hormone replacement therapy is to protect the endometrium against hyperplasia. In this paper we review data that demonstrate that hormone replacement therapy that includes norethisterone acetate has positive effects on the postmenopausal bone metabolism and that it increases bone mass more than expected and more than treatment with alendronate. All available evidence is reviewed to show that norethisterone acetate, if given in the correct dosage, does not influence serum lipids and lipoproteins in any negative way. It is furthermore shown that norethisterone acetate seems to be superior compared to other progestogens to provide optimum bleeding control and endometrial protection. Also, hormone replacement therapy combinations with norethisterone acetate efficiently alleviate hot flushes. Hormone replacement therapy and the risk of breast cancer and the role of progestogens are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12389012     DOI: 10.1067/mob.2002.122852

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

Review 1.  Endometriosis: current therapies and new pharmacological developments.

Authors:  Paolo Vercellini; Edgardo Somigliana; Paola Viganò; Annalisa Abbiati; Giussy Barbara; Pier Giorgio Crosignani
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial.

Authors:  Simone Ferrero; Pier L Venturini; David J Gillott; Valentino Remorgida
Journal:  Reprod Biol Endocrinol       Date:  2011-06-21       Impact factor: 5.211

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.